Opioids Sales

Opioids Sales Market Outlook

The global opioids sales market is projected to reach a valuation of approximately USD 38.5 billion by 2035, growing at a CAGR of 5.6% during the forecast period of 2025-2035. The increasing prevalence of chronic pain conditions has been a significant driving factor behind this growth, as healthcare providers increasingly prescribe opioids for pain management therapies. Furthermore, the rise in geriatric populations, who are more susceptible to chronic pain and require effective management solutions, has contributed substantially to the market's expansion. The ongoing developments in the pharmaceutical sector, including innovative drug formulations and advancements in delivery methods, are also expected to augment the market growth. Additionally, the rising acceptance of opioids in various clinical applications, such as anesthesia and cough suppression, further bolsters the demand in the market.

Growth Factor of the Market

One of the primary growth factors for the opioids sales market is the increasing incidence of pain-related disorders, such as arthritis, cancer, and postoperative pain, which compels healthcare professionals to explore various treatment options, including opioid prescriptions. Furthermore, the acceptance of opioids as essential medications for managing pain, particularly in surgical and palliative care settings, drives demand significantly. Technological advancements in drug formulation and delivery mechanisms have also enhanced the efficacy and safety profiles of opioids, making them more appealing to healthcare practitioners. The rise in outpatient surgeries and patients’ preferences for pain management strategies that allow for quicker recovery, such as opioids, are contributing to market growth. Lastly, legislative changes in several regions aimed at balancing the management of pain with the risks of addiction and misuse are influencing the market landscape, leading to more refined prescribing practices and encouraging the development of diversifying opioid alternatives.

Key Highlights of the Market

• The opioids sales market is expected to witness a CAGR of 5.6% from 2025 to 2035.
• North America remains the largest market contributor due to high prescription rates and advanced healthcare infrastructure.
• Product types like oxycodone and fentanyl are witnessing increased adoption for pain management applications.
• Recent regulatory measures aim to mitigate misuse while ensuring adequate pain management for patients.
• The trend towards online pharmacies for opioid distribution is on the rise, leading to greater accessibility for patients.

By Product Type

Oxycodone:

Oxycodone is a potent semi-synthetic opioid that is highly prescribed for the management of moderate to severe pain. Its effectiveness in treating pain, particularly in cancer patients and those recovering from surgery, has led to its widespread acceptance among healthcare providers. As the market continues to grow, the demand for oxycodone is expected to remain robust, especially due to its versatile formulations, including extended-release options that provide longer-lasting pain relief. Additionally, the growing awareness of pain management strategies is likely to boost the sales figures for oxycodone, despite the growing concern regarding its potential for misuse and addiction.

Hydrocodone:

Hydrocodone serves as another significant product type within the opioids sales market, primarily used to manage moderate pain and as a cough suppressant. Its combination with acetaminophen in various formulations makes it a popular choice among clinicians treating pain. The increasing number of prescriptions for hydrocodone, driven by its efficacy and relative safety profile compared to stronger opioids, is a pivotal factor in maintaining steady growth in this segment. Hydrocodone's formulation flexibility, including syrups and tablets, further contributes to its market appeal, keeping it relevant in the evolving landscape of pain management solutions.

Codeine:

Codeine, a naturally occurring opioid, is commonly used for treating mild to moderate pain and as a cough suppressant. Its position in the market is bolstered by its long history of use and its lower potency compared to other opioids. The demand for codeine remains consistent, particularly in settings where lower levels of pain relief are needed or for patients who are sensitive to stronger opioids. The increased availability of combination medications containing codeine also enhances its appeal, making it a staple in prescriptions for pain relief. However, potential side effects and the risk of addiction necessitate careful prescribing practices to mitigate misuse.

Morphine:

Morphine remains one of the oldest and most potent opioids used for managing severe pain, particularly in hospital settings for post-operative care and cancer treatment. Its reputation as a reliable pain management solution ensures that it retains a significant market share, especially for patients requiring high doses under strict medical supervision. The development of new delivery methods, such as transdermal patches, has further enhanced morphine's marketability by providing sustained pain relief while reducing the need for frequent dosing. As the demand for strong pain management solutions persists, morphine's role in the market is expected to grow, driven by its effectiveness and established presence in treatment protocols.

Fentanyl:

Fentanyl, a powerful synthetic opioid, has gained momentum in the opioids sales market due to its effectiveness in managing severe pain, particularly in chronic pain patients and during surgical procedures. Its rapid onset and potency make it a go-to choice for healthcare providers, albeit with cautious prescribing due to heightened risks associated with its misuse. The availability of various formulations, including patches, lozenges, and injectable forms, allows for flexibility in pain management strategies, catering to the diverse needs of patients. As awareness and training surrounding fentanyl usage continue to evolve, its market share is likely to expand, particularly in pain management and anesthetic applications.

By Application

Pain Management:

Pain management is the primary application driving the opioids sales market, as these medications are specifically designed to alleviate pain symptoms associated with various conditions, including acute and chronic pain disorders. In clinical practices, opioids are often utilized in multimodal approaches to manage pain effectively, especially in surgical recovery, cancer treatment, and palliative care scenarios. The rising incidence of chronic pain conditions, coupled with an aging population, has led to a growing reliance on opioids for effective pain relief. The increasing recognition of the need for effective pain management strategies reinforces the significance of this application in the overall opioid market.

Anesthesia:

The use of opioids in anesthesia is another vital application contributing to the market's growth. Opioids play a crucial role as part of balanced anesthesia techniques, providing analgesia during surgeries and other invasive procedures. Their ability to enhance the overall quality of anesthesia while minimizing the use of general anesthetics makes them indispensable in surgical settings. The ongoing advancements in surgical techniques and outpatient procedures further bolster the demand for opioids in anesthesia. As surgical procedures become more refined and minimally invasive, the reliance on effective opioids for anesthesia is likely to remain a key driver in the market.

Cough Suppressant:

Opioids are also employed as cough suppressants, particularly in cases where other medications may not provide adequate relief. The application of opioids for managing severe coughs, especially those associated with conditions like bronchitis or post-viral syndromes, maintains a steady demand. Codeine, in particular, has been widely recognized for its efficacy as a cough suppressant, leading to its continued utilization in this application. As healthcare providers seek effective solutions for patients suffering from persistent coughs, the role of opioids in this domain is likely to persist, contributing positively to the overall sales market.

Diarrhea Suppressant:

Opioids are also indicated for use as diarrhea suppressants, particularly in the management of acute diarrhea by slowing gut motility. Medications such as loperamide, although not classified as a traditional opioid, act on similar receptors to mitigate diarrhea symptoms. The persistent demand for effective treatments for gastrointestinal disorders ensures that this application remains relevant within the opioids sales market. Healthcare providers often turn to opioids in cases where other treatments fail, further solidifying their role in managing gastrointestinal symptoms. The focus on patient-centric approaches to healthcare continues to promote the relevance of opioids in various applications, including diarrhea suppression.

Others:

In addition to the key applications mentioned, opioids find utility in various other therapeutic areas, including the treatment of anxiety and certain mood disorders. The broad spectrum of applications for opioids, especially in non-pain-related conditions, continues to expand as research uncovers new treatment potentials. The adaptability of opioids in addressing complex patient needs serves as a crucial factor driving market growth. Ongoing clinical trials and studies aim to explore the diverse benefits of opioids, ultimately contributing to their market presence across multiple health conditions, thereby reinforcing their importance in modern medicine.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies play a pivotal role in the distribution of opioids, as they are integral to inpatient care and pain management protocols. Within hospital settings, opioids are prescribed and administered under strict supervision, ensuring patient safety while providing effective pain relief. The increasing volume of surgical procedures and inpatient admissions has further amplified the reliance on hospital pharmacies for opioid distribution. As healthcare facilities focus on enhancing patient care and pain management strategies, hospital pharmacies will continue to be a significant channel in the opioids sales market, addressing the immediate needs of patients requiring intensive pain management.

Retail Pharmacies:

Retail pharmacies are essential distribution channels for opioids, catering to outpatients and chronic pain patients seeking medication refills. The accessibility and convenience of retail pharmacies make them a preferred choice for patients managing ongoing pain conditions. Retail pharmacies often serve as the first point of contact for patients, providing consultations and prescription fulfillment under regulatory guidelines. The growing trend of personalized medicine and patient-centric services will likely enhance the role of retail pharmacies in the opioids market, ensuring that patients receive the necessary medications while being guided on safe usage practices.

Online Pharmacies:

The emergence of online pharmacies has transformed the distribution landscape of opioids, providing patients with greater accessibility to necessary medications. The convenience of ordering prescriptions online allows patients to manage their medications discreetly while maintaining a level of privacy and comfort. However, the rise of online pharmacies has brought concerns regarding the potential for misuse and inadequate oversight. Regulatory bodies are increasingly focusing on ensuring that online pharmacies adhere to strict guidelines, ensuring that patients receive medications safely. As technology continues to influence healthcare delivery, the role of online pharmacies will likely expand, creating an innovative approach to opioid distribution.

Drug Stores:

Drug stores serve as an essential distribution channel for opioids, offering patients access to a variety of medications, including over-the-counter and prescription drugs. The presence of trained pharmacists in drug stores ensures that patients receive appropriate counseling and guidance on opioid usage, enhancing patient safety. Drug stores often function in tandem with retail pharmacies, offering convenience and accessibility for patients managing pain conditions. Furthermore, the expansion of drug store chains across various regions supports the growing demand for opioids, enabling patients to obtain necessary medications in a more efficient manner.

Others:

In addition to the primary distribution channels, there exist other avenues through which opioids may reach patients, including direct-to-consumer marketing and specialty pharmacies. Specialty pharmacies cater to patients with complex medications, including those requiring opioids, by providing tailored services and education. The diversification of distribution channels reflects the evolving landscape of the healthcare system, where patient needs continue to take precedence. As the opioids sales market adapts to these changing dynamics, the emergence of alternative distribution methods will play a critical role in ensuring that patients receive effective medications while adhering to safety protocols.

By Ingredient Type

Natural Opioids:

Natural opioids, derived from the opium poppy, encompass well-known substances such as morphine and codeine. These compounds have been used for centuries in pain management and are recognized for their efficacy in treating severe pain. The natural origin of these opioids appeals to certain patient populations who may prefer alternatives to synthetic medications. As the demand for pain relief options persists, natural opioids will maintain a significant presence in the market, supported by ongoing research into their therapeutic applications. However, the challenge of potential addiction and side effects remains a crucial consideration for healthcare providers when prescribing natural opioids.

Semi-Synthetic Opioids:

Semi-synthetic opioids, including oxycodone and hydrocodone, have revolutionized pain management with their enhanced efficacy and versatility. These opioids are synthesized from natural opiates, allowing for the development of formulations tailored to specific patient needs. The growing use of semi-synthetic opioids can be attributed to their effectiveness in managing moderate to severe pain and their ability to be combined with non-opioid analgesics for improved outcomes. As patient awareness of pain management options increases, the demand for semi-synthetic opioids will likely continue to rise, particularly in outpatient settings and chronic pain management scenarios.

Fully Synthetic Opioids:

Fully synthetic opioids, such as fentanyl, are artificially created to provide potent pain relief, especially in surgical and cancer care settings. Their rapid onset and high potency make them essential in managing severe pain; however, they are also associated with a higher risk of abuse and overdose. The growing preference for fully synthetic opioids in acute pain management scenarios is driven by their efficacy, but their use is closely monitored due to the associated risks. The ongoing research and development of safer formulations aim to mitigate these concerns while ensuring effective pain management solutions for patients requiring high doses of opioids.

By Region

North America is the largest market for opioids, accounting for over 45% of the global market share due to a high prevalence of chronic pain conditions and a well-established healthcare infrastructure. The U.S. specifically has demonstrated a significant reliance on opioids for pain management, which has led to increasing scrutiny and regulations around their prescription. The market in North America is projected to grow at a CAGR of 5.8% through 2035, fueled by ongoing advancements in pain management practices and efforts to address opioid misuse through education and responsible prescribing. Additionally, the rise of telemedicine and online pharmacies will enhance access to opioids for patients managing chronic pain.

In Europe, the opioids sales market is also witnessing substantial growth, with an increasing emphasis on pain management strategies among healthcare providers. The market's expansion can be attributed to the rising geriatric population, which often suffers from chronic pain, alongside the acceptance of opioids in various therapeutic applications. The European market is expected to grow at a CAGR of 5.2% during the forecast period, as governments and health organizations continue to support the effective use of opioids while addressing concerns related to addiction and misuse. The convergence of healthcare systems and the ongoing push for integrated pain management approaches will support the growth of the opioids sales market across Europe.

Opportunities

The opioids sales market presents numerous opportunities, particularly in the development of new formulations that address the concerns surrounding addiction and misuse. Pharmaceutical companies are increasingly investing in research and development to create abuse-deterrent formulations, which could significantly expand the market potential for opioids. These innovative approaches aim to provide effective pain relief while minimizing the risk of dependence and addiction, making opioids a more viable option for both patients and healthcare providers. Additionally, the integration of technology in pain management, such as telehealth services and mobile applications, offers opportunities for improved monitoring and support for opioid use, leading to better patient outcomes and enhanced safety protocols.

Moreover, the growing acceptance of opioids in various clinical applications beyond traditional pain management creates further opportunities within the market. For instance, as research continues to uncover potential benefits of opioids in treating conditions such as anxiety and other mood disorders, the scope for opioids to be prescribed in different contexts expands. The ongoing evolution of healthcare policies aiming to balance pain management with responsible prescribing practices presents a unique opportunity for the opioids sales market to adapt and thrive, leading to the development of innovative solutions addressing patient needs while ensuring safety and efficacy.

Threats

Despite the promising growth prospects for the opioids sales market, there are inherent threats that could hinder its overall trajectory. One of the most significant challenges is the ongoing opioid crisis, characterized by escalating rates of addiction and overdose. The public health implications of opioid misuse have led to increased scrutiny and regulation surrounding opioid prescriptions, which may result in reduced access for legitimate patients who require these medications for effective pain management. As regulatory bodies impose stricter guidelines and limitations around opioid usage, the market may face challenges in maintaining growth, with healthcare providers potentially hesitant to prescribe these medications. Additionally, the stigma surrounding opioid use could further dissuade patients from seeking necessary pain relief, impacting overall market potential.

Moreover, the emergence of non-opioid pain relief alternatives poses a threat to the opioids sales market. Advancements in medical technology and pharmaceutical research have led to the development of various alternative pain management solutions, such as non-steroidal anti-inflammatory drugs (NSAIDs), physical therapy, and even psychological interventions. As patients increasingly turn to these alternatives, the market for opioids may experience challenges in maintaining its historical growth trajectory. The competition from these alternative treatment options highlights the importance of ensuring that opioids are prescribed responsibly and effectively, addressing the need for pain management while mitigating the risks associated with their use.

Competitor Outlook

• Purdue Pharma
• Johnson & Johnson
• Mallinckrodt Pharmaceuticals
• Teva Pharmaceutical Industries
• Endo International
• Amgen Inc.
• Pfizer Inc.
• AbbVie Inc.
• Hikma Pharmaceuticals
• GSK (GlaxoSmithKline)
• Novartis AG
• Boehringer Ingelheim
• Roche Holding AG
• Sun Pharmaceutical Industries
• Sanofi S.A.

The competitive landscape of the opioids sales market is characterized by several key players who dominate the industry by providing a range of opioid formulations and applications. Major pharmaceutical companies, such as Purdue Pharma and Johnson & Johnson, have historically led the market due to their extensive portfolios of pain management products. These companies invest heavily in research and development to ensure that they remain at the forefront of innovation while addressing the critical issues surrounding opioid use, including abuse and addiction. The competitive dynamics within the market are shaped by the ongoing need for responsible prescribing practices and the development of alternative therapies to mitigate the risks associated with opioid use.

Moreover, companies like Mallinckrodt Pharmaceuticals and Teva Pharmaceutical Industries have also established themselves as formidable players in the opioids market, leveraging their diverse product offerings to cater to various patient needs. These firms focus on providing a range of formulations, including immediate-release and extended-release options, allowing healthcare providers to tailor their pain management strategies accordingly. The increasing emphasis on abuse-deterrent formulations among competitors signifies a collective effort to enhance patient safety and reduce the risk of substance misuse, which remains a priority within the industry.

In conclusion, as the opioids market continues to evolve, companies such as AbbVie Inc. and Pfizer Inc. are keen to explore new therapeutic avenues and market opportunities that align with changing patient needs and regulations. The growing focus on alternative therapies, patient education, and the integration of technology into pain management solutions are pivotal trends shaping the competitive landscape. Staying ahead of regulatory changes and fostering collaboration with healthcare providers will be essential for companies to maintain their competitive edge while addressing the complexities of opioid management in today's healthcare environment.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 AbbVie Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Novartis AG
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Pfizer Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Sanofi S.A.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Purdue Pharma
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Roche Holding AG
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Johnson & Johnson
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Endo International
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Boehringer Ingelheim
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 GSK (GlaxoSmithKline)
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Hikma Pharmaceuticals
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Mallinckrodt Pharmaceuticals
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Sun Pharmaceutical Industries
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Opioids Sales Market, By Application
    • 6.1.1 Pain Management
    • 6.1.2 Anesthesia
    • 6.1.3 Cough Suppressant
    • 6.1.4 Diarrhea Suppressant
    • 6.1.5 Others
  • 6.2 Opioids Sales Market, By Product Type
    • 6.2.1 Oxycodone
    • 6.2.2 Hydrocodone
    • 6.2.3 Codeine
    • 6.2.4 Morphine
    • 6.2.5 Fentanyl
  • 6.3 Opioids Sales Market, By Ingredient Type
    • 6.3.1 Natural Opioids
    • 6.3.2 Semi-Synthetic Opioids
    • 6.3.3 Fully Synthetic Opioids
  • 6.4 Opioids Sales Market, By Distribution Channel
    • 6.4.1 Hospital Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies
    • 6.4.4 Drug Stores
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Opioids Sales Market by Region
  • 10.4 Latin America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 Brazil
      • 10.4.1.2 Argentina
      • 10.4.1.3 Mexico
  • 10.5 North America - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 USA
      • 10.5.1.2 Canada
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Opioids Sales market is categorized based on

By Product Type

• Oxycodone
• Hydrocodone
• Codeine
• Morphine
• Fentanyl

By Application

• Pain Management
• Anesthesia
• Cough Suppressant
• Diarrhea Suppressant
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Drug Stores
• Others

By Ingredient Type

• Natural Opioids
• Semi-Synthetic Opioids
• Fully Synthetic Opioids

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Purdue Pharma
• Johnson & Johnson
• Mallinckrodt Pharmaceuticals
• Teva Pharmaceutical Industries
• Endo International
• Amgen Inc.
• Pfizer Inc.
• AbbVie Inc.
• Hikma Pharmaceuticals
• GSK (GlaxoSmithKline)
• Novartis AG
• Boehringer Ingelheim
• Roche Holding AG
• Sun Pharmaceutical Industries
• Sanofi S.A.